Emergence of Myasthenia Gravis During Treatment With Lithium Carbonate
- 1 September 1976
- journal article
- case report
- Published by American Medical Association (AMA) in Archives of General Psychiatry
- Vol. 33 (9), 1090-1092
- https://doi.org/10.1001/archpsyc.1976.01770090080007
Abstract
• In a patient with recurrent episodes of severe mania, classical manifestations of myasthenia gravis developed for the first time during treatment with lithium carbonate. Four episodes were recorded in which the appearance of progressive weakness coincided with subacute or long-term lithium carbonate administration during periods of psychiatric remission. In each instance, neurologic symptoms were ameliorated or disappeared shortly after the drug was discontinued or its dosage was reduced. There was no evidence of lithium carbonate toxicity or electrolyte disturbances at any time during treatment. Based on a literature review of animal studies and related clinical reports, a mechanism of peripherally mediated neuromuscular cholinergic insufficiency is proposed. In addition, the differential diagnosis of muscle weakness during lithium carbonate administration is discussed.Keywords
This publication has 7 references indexed in Scilit:
- Psychopharmacologic management of patients: a method for recording treatment decisionsAmerican Journal of Psychiatry, 1975
- The use of pancuronium bromide in patients receiving lithium carbonateCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 1974
- Development and Application of the KDS™-1 in Inpatient and Outpatient SettingsPsychological Reports, 1971
- Once more‐On the extraordinary side effects of drugsClinical Pharmacology & Therapeutics, 1971
- Neurotoxicity with Lithium: Differential Drug ResponsivenessInternational Pharmacopsychiatry, 1970
- Paroxysmale Muskelschwäche bei Lithiumtherapie*Pharmacopsychiatry, 1969
- THE EFFECTS OF LITHIUM ON THE NEUROMUSCULAR JUNCTION OF THE FROGThe Japanese Journal of Physiology, 1966